Purpose: To assess IOP-lowering efficacy of bimatoprost/timolol fixed combination (Ganfort®) in patients with diabetes mellitus (DM) and uncontrolled secondary neovascular glaucoma
Materials and Methods: Fifty patients (51 eyes) with uncontrolled secondary neovascular glaucoma
and diabetes mellitus were enrolled in the study. All patients with an uncontrolled IOP have been
proposed to switch current IOP-lowering therapy to Ganfort®. In case target IOP level was not reached
filtration surgery was recommended. Ganfort® administration - once a day in the morning.
Results: IOP-lowering has been observed in all patients when switched to Ganfort®. Mean IOP level was almost 3-x
lower versus baseline in 72.5% of patients (37 eyes). The patients achieved target IOP of 15-17 mmHg. As a result, no
surgical intervention was required. Significant IOP-lowering has been observed in another group of patients (14 eyes, 27.5
%) nevertheless due to glaucoma progression, these patients are still subjected to surgical treatment.
Conclusion: IOP-lowering fixed combination Ganfort® (Allergan) can be used in patients with secondary neovascular
glaucoma and diabetes mellitus as a drug of choice to control the IOP level. Even in cases when target IOP is not
achieved, Ganfort® can be administered in pre-operative period and helps to reduce postoperative complications.